<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00500708</url>
  </required_header>
  <id_info>
    <org_study_id>CDX_000003</org_study_id>
    <secondary_id>DISCERN</secondary_id>
    <nct_id>NCT00500708</nct_id>
  </id_info>
  <brief_title>Diagnostic Investigation of Sudden Cardiac Event Risk</brief_title>
  <acronym>DISCERN</acronym>
  <official_title>Identifying Markers That Predict Ventricular Arrhythmia Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CardioDx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CardioDx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of the DISCERN study is to develop and validate a genomic diagnostic
      assay to identify patients at increased risk for lethal ventricular arrhythmias and sudden
      cardiac death (SCD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, observational study. The research will be performed in
      three phases, each using distinct patient cohorts:

      Phase I: Discovery - genes/biomarkers/clinical factors Phase II: Algorithm Development Phase
      III: Assay Validation

      The final algorithm (Assay) may incorporate a combination of factors including genetic
      markers, biomarker(s), and clinical factor(s). Participation in the study does not alter
      clinical care. The procedures required by the protocol are collection of a research blood
      sample (at baseline only) and interviews with the subject to collect specific clinical
      information at baseline and follow-up (6 mos, 1 yr, 2 yr, 3 yr, 4 yr, and 5 yr) after
      enrollment. All other data collected is in accordance with the participating institution's
      standard patient care.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">August 1, 2011</completion_date>
  <primary_completion_date type="Actual">August 1, 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Gene discovery</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Genome Wide Association Study (GWAS)</description>
  </primary_outcome>
  <enrollment type="Actual">1564</enrollment>
  <condition>Arrhythmia</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Heart Failure</condition>
  <condition>CVD</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, buffy coat, spun plasma, saliva
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patient's with ventricular dysfunction (low ejection fraction) undergoing implantation of
        ICD or CRT-D for primary prevention. Patient's may be enrolled at time of implant or during
        follow-up in electrophysiology clinic as long as full device records are available since
        time of implant.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Implantable cardiac defibrilIator (ICD) or cardiac resynchronization therapy
             defibrillator (CRT-D) implanted for primary prevention

          -  Left ventricular ejection fraction (LVEF) â‰¤ 50 %

          -  Ability to collect clinical follow-up and endpoint information, including device
             interrogation data

        Exclusion Criteria:

          -  Congenital heart disease

          -  Known inherited arrhythmia disorder

          -  Organ transplantation

          -  Inability to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Zapien, MS</last_name>
    <role>Study Director</role>
    <affiliation>CardioDx, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alaska Heart Institute</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palo Alto Medical Foundation</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute and Foundation</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Penn Allegheny Health System</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Healthcare</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hranitzky PM, Sehnert AJ, Blanchard JL, et al. Abstract 16410: Identification of novel genetic markers associated with lethal ventricular arrhythmias in heart failure patients: genome wide association study in the DISCERN cohort. Circulation. 2010;122. Abstract 16410.</citation>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2007</study_first_submitted>
  <study_first_submitted_qc>July 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2007</study_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Implanted Cardioverter Defibrillator</keyword>
  <keyword>Biological Markers</keyword>
  <keyword>Molecular Genetics</keyword>
  <keyword>Coronary Heart Disease</keyword>
  <keyword>Gene Expression</keyword>
  <keyword>GES</keyword>
  <keyword>CVD</keyword>
  <keyword>CHD</keyword>
  <keyword>Precision Medicine</keyword>
  <keyword>Genome-wide association study</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>CAD</keyword>
  <keyword>GWAS</keyword>
  <keyword>DISCERN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

